Breaking News

Cobra Biologics Appoints CSO

May 7, 2014

Smith to develop scientific excellence and enhance R&D platforms

Dr. Daniel C. Smith has been appointed chief scientific officer at Cobra Biologics, with responsibility for developing scientific excellence across the group and enhancing Cobra’s DNA, virus, microbial and mammalian proteins R&D platforms.
Dr. Smith joins the company from HealthTech & Medicines Knowledge Transfer Network (KTN), where he served as a Knowledge Transfer Manager on the bioProcessUK team, responsible for driving the innovation agenda for biologics bioprocessing in the UK. Previously, Dr. Smith held a variety of roles progressing from senior scientist to commercial scientific development manager, responsible for developing the strategy for customer’s projects, and maintaining scientific oversight of Cobra’s R&D projects.
Peter Coleman, chief executive officer at Cobra Biologics, said, “This is a significant appointment for Cobra and I am personally very pleased that Dan has decided to return to Cobra as our new CSO. He has a tremendous enthusiasm for science and its application in our industry and from working with him previously, I firmly believe he has experience and ability to further establish Cobra as a leading scientific organization.”

blog comments powered by Disqus